Epirus Biopharmaceuticals Inc., a U.S. biotech focused exclusively on biosimilars, is partnering with Polish generics titan Polpharma SA to develop and commercialize biosimilars of three anti-inflammatory blockbusters in a deal that analysts are hailing as another step in a well thought-out and executed strategy in a highly competitive sector.
In a deal announced July 14, Boston-based Epirus is teaming with privately held Polpharma on biosimilar versions of Johnson & Johnson’s Remicade (infliximab), AbbVie Inc
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?